Title: Long-Term Safety of Brazikumab in the Open-Label Period of a Randomized Phase 2a
Study of Patients With Crohn’s Disease
Version: 2 Date: 13 Nov 2023
Reviewer:  Nikolas Dussias
Reviewer's report:
This manuscript regards the long-term safety and tolerability of brazikumab in patients wtih
moderate to severe Crohn's disease over a 100 week follow-up period. The study involves a
cohort of patients who completed a 12-week double-blind induction period and transitioned
to an open-label phase. The manuscript is comprehensive, covering patient demographics,
methodology, treatment safety, pharmacokinetics, immunogenicity, and clinical efficacy.  The
focus on treatment-emergent adverse events, infections, and serious adverse events is pertinent.
The results are presented in an organized  manner, and comparison of safety data with other
IL-23 inhibitors adds value. In conclusion, in this manuscript the authors provide important
information regarding long-term safety aspects of brazikumab.
Title: Long-Term Safety of Brazikumab in the Open-Label Period of a Randomized Phase 2a
Study of Patients With Crohn’s Disease
Version: 2 Date: 13 Nov 2023
Reviewer:  Nikolas Dussias
Reviewer's report:
This manuscript regards the long-term safety and tolerability of brazikumab in patients wtih
moderate to severe Crohn's disease over a 100 week follow-up period. The study involves a
cohort of patients who completed a 12-week double-blind induction period and transitioned
to an open-label phase. The manuscript is comprehensive, covering patient demographics,
methodology, treatment safety, pharmacokinetics, immunogenicity, and clinical efficacy.  The
focus on treatment-emergent adverse events, infections, and serious adverse events is pertinent.
The results are presented in an organized  manner, and comparison of safety data with other
IL-23 inhibitors adds value. In conclusion, in this manuscript the authors provide important
information regarding long-term safety aspects of brazikumab.
Please review this paper.
user
Title: Long-Term Safety of Brazikumab in the Open-Label Period of a Randomized Phase 2a
Study of Patients With Crohn’s Disease
Version: 2 Date: 13 Nov 2023
Reviewer:  Nikolas Dussias
Reviewer's report:
This manuscript regards the long-term safety and tolerability of brazikumab in patients wtih
moderate to severe Crohn's disease over a 100 week follow-up period. The study involves a
cohort of patients who completed a 12-week double-blind induction period and transitioned
to an open-label phase. The manuscript is comprehensive, covering patient demographics,
methodology, treatment safety, pharmacokinetics, immunogenicity, and clinical efficacy.  The
focus on treatment-emergent adverse events, infections, and serious adverse events is pertinent.
The results are presented in an organized  manner, and comparison of safety data with other
IL-23 inhibitors adds value. In conclusion, in this manuscript the authors provide important
information regarding long-term safety aspects of brazikumab.
assistant